title: Deferred therapy in patients with advanced disease.
abstract: Disease that is known to have extended beyond the prostatic capsule is unlikely to be cured by radical surgical excision, although the primary tumor may be controlled by external irradiation. The development of progressive (metastatic) disease is common and may be retarded by hormonal therapy. The timing of such treatment and the debate about monotherapy versus total androgen ablation has not been resolved fully. It is considered further in this article.
authors.affiliation: St. James's University Hospital, Leeds, United Kingdom.
authors.forename: P H
authors.initials: PH
authors.lastname: Smith
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008017:Life Expectancy; D008207:Lymphatic Metastasis; D008297:Male; D009367:Neoplasm Staging; D009919:Orchiectomy; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone